Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Trial Profile

Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 Dec 2017 According to a Novo Nordisk media release, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes mellitus.
    • 08 Dec 2017 Results evaluate the potential of semaglutide in helping subjects achieve HbA1c targets, additional analyses were performed with data from the SUSTAIN 1-5 trials, were presented at the 2017 Congress of the International Diabetes Federation.
    • 08 Dec 2017 Results assessing the effect of once-weekly subcutaneous semaglutide on FPG and PPG across the SUSTAIN 1-5 trials, were presented at the 2017 Congress of the International Diabetes Federation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top